Moscow, May 24, 2021: The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, today announced the launch of full-scale production of the Russian Sputnik V vaccine in India.

According to the press release, the first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine will start this summer.Company’s facilities comply with GMP (Good Manufacturing practice) standards and are prequalified by WHO.

In India the Sputnik V was registered under the emergency use authorization procedure on April 12, 2021 and its vaccination against coronavirus started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V.

Sputnik V Vaccine launch in India

Sputnik V Covid19 vaccine is registered in 66 countries around the world and has a efficacy rate of 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021. Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

The CEO of RDIF (Russian Direct Investment Fund) Kirill Dmitriev said that “Launch of production in India in partnership with Panacea Biotec marks an important step in helping the country fight the pandemic. Production of Sputnik V supports efforts of India’s authorities to leave behind the acute phase of coronavirus as soon as possible while the vaccine will also be exported at a later stage to help prevent the spread of the virus in other countries around the world.”

The managing director of Panacea Biotec, Dr. Rajesh Jain also made a statement that, “This marks a significant step as we initiate production of Sputnik V. Together with RDIF, we hope to help bring a sense of normalcy back to people across the country and around the world.”

As India is currently struggling to provide for Vaccine shortages in several states and union territories, full-scale production of a vaccine like Sputnik V can go a long way in ramping up vaccine production in India to meet the increasing demand for vaccines. Additionally the russian side has also announced plans to ship 18 million doses of vaccine to India, however demands from around the world questions their ability to fulfill such

Isha S Saha

By Isha S Saha

Journalism student at Christ University. Passionate about telling stories of common people.

4 thoughts on “RDIF and Panacea Bio-tech to launch full scale production of Sputnik V Covid-19 vaccine in India”
  1. […] As per the statement by the Ministry of External Affairs, Jaishankar will also be meeting Cabinet members and Senior Officials of the Administration dealing with the bilateral relationship. The External Affairs Minister will have two interactions with business forums on economic & COVID-related cooperation between India and the US. […]

Your comments